Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRGXNASDAQ:IPSCNASDAQ:SLSNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$4.70+3.0%$4.25$3.00▼$25.45$216.26M0.31557,688 shs688,504 shsIPSCCentury Therapeutics$0.62+9.9%$0.52$0.34▼$3.46$55.66M1.77502,688 shs1.05 million shsSLSSELLAS Life Sciences Group$1.63-0.3%$1.46$0.77▼$2.12$163.14M2.251.56 million shs1.04 million shsSOPHSOPHiA GENETICS$3.14+3.0%$2.96$2.58▼$5.22$209.40M153,150 shs15,006 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics+0.22%+8.06%+11.76%+15.15%-75.96%IPSCCentury Therapeutics-0.71%+1.08%+6.03%-14.10%-81.23%SLSSELLAS Life Sciences Group+1.87%-4.68%-5.23%+36.97%+10.14%SOPHSOPHiA GENETICS+1.67%+6.27%+1.67%-5.86%-40.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics2.2561 of 5 stars2.90.00.00.03.11.71.3IPSCCentury Therapeutics2.6604 of 5 stars3.53.00.00.02.71.70.6SLSSELLAS Life Sciences Group0.3642 of 5 stars0.01.00.00.02.01.70.6SOPHSOPHiA GENETICS2.1323 of 5 stars3.45.00.00.01.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics 1.86Reduce$15.00219.49% UpsideIPSCCentury Therapeutics 3.00Buy$4.20578.51% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ASOPHSOPHiA GENETICS 2.75Moderate Buy$6.80116.56% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, SOPH, CRGX, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.004/3/2025IPSCCentury TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.003/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.003/21/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025IPSCCentury TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.00 ➝ $2.003/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/AIPSCCentury Therapeutics$114.90M0.46N/AN/A$3.06 per share0.20SLSSELLAS Life Sciences Group$1M162.14N/AN/A($0.25) per share-6.50SOPHSOPHiA GENETICS$67.17M3.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$98.15M-$4.62N/AN/AN/AN/A-38.16%-33.94%8/11/2025 (Estimated)IPSCCentury Therapeutics-$136.67M-$0.29N/AN/AN/A-4,837.73%-61.66%-31.78%8/14/2025 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)SOPHSOPHiA GENETICS-$78.98M-$1.00N/AN/AN/A-110.71%-55.06%-38.33%8/5/2025 (Estimated)Latest IPSC, SOPH, CRGX, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A18.9418.95IPSCCentury TherapeuticsN/A10.3910.39SLSSELLAS Life Sciences GroupN/A2.262.26SOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%IPSCCentury Therapeutics50.20%SLSSELLAS Life Sciences Group17.38%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics2.92%IPSCCentury Therapeutics6.80%SLSSELLAS Life Sciences Group1.40%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11646.11 million45.39 millionN/AIPSCCentury Therapeutics17086.16 million79.25 millionOptionableSLSSELLAS Life Sciences Group1099.78 million69.54 millionNot OptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableIPSC, SOPH, CRGX, and SLS HeadlinesRecent News About These CompaniesM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3 at 8:26 PM | zawya.comM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3 at 8:26 PM | msn.comM42, partners launch liquid biopsy testing in UAEJune 3 at 4:58 AM | tradearabia.comThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateJune 1, 2025 | marketbeat.com'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSupreme Court: IVF mixup baby to remain with birth parentsMay 12, 2025 | israelnationalnews.comSupreme Court upholds decision to keep IVF child with birth mother following embryo mix-upMay 12, 2025 | msn.comSupreme Court rules birth parents of child born in IVF mix-up are legal parentsMay 12, 2025 | msn.comThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10, 2025 | blogs.timesofisrael.comSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSOPHiA GENETICS (NASDAQ:SOPH) Releases Earnings Results, Misses Expectations By $0.05 EPSMay 8, 2025 | marketbeat.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comSOPHiA GENETICS Reports First Quarter 2025 ResultsMay 6, 2025 | prnewswire.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30, 2025 | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025April 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, SOPH, CRGX, and SLS Company DescriptionsCARGO Therapeutics NASDAQ:CRGX$4.70 +0.14 (+2.96%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Century Therapeutics NASDAQ:IPSC$0.62 +0.06 (+9.95%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.SELLAS Life Sciences Group NASDAQ:SLS$1.62 -0.01 (-0.31%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.SOPHiA GENETICS NASDAQ:SOPH$3.14 +0.09 (+2.95%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Market’s Silent Warning: What Bonds and Gold Reveal AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
